Prescribing information


Cosentyx is indicated for the treatment of: moderate to severe plaque psoriasis in adults who are candidates for systemic therapy; active psoriatic arthritis in adult patients, alone or in combination with MTX, when the response to previous DMARD therapy has been inadequate; active ankylosing spondylitis in adults who have responded inadequately to conventional therapy; active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated CRP and/or MRI evidence in adults who have responded inadequately to NSAIDs.

Help your newly initiated Cosentyx patients keep track of their treatment with a digital dosing schedule. As a healthcare professional, you should download the document and fill in the patient’s planned injection dates, as shown in the example below.

Share the completed file with your patients and they can simply tick the circles after they administer their Cosentyx dose, as shown in the example below:

Image of example patient dosing schedule which has been completed by patient and doctor

Please note that this resource is designed for optimal use on desktop or tablet. Functionality may be restricted on some devices including mobile. 

Do not share links to this website or screenshots with patients as this website is intended for healthcare professionals only.





For more information on Cosentyx dosing, please see dosing and product information.

CRP, C-reactive protein; DMARD, disease-modifying anti-rheumatic drug; MRI, magnetic resonance imaging; MTX, methotrexate; NSAIDs, non-steroidal anti-inflammatory drugs.

Rate this content: 
No votes yet
UK | March 2021 | 104092

Ask Speakers


Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]